Efficacy of contrast-enhanced ultrasonography in radiofrequency ablation for hepatocellular carcinoma

Internal Medicine

Volumn 51, Issue 1, 2012, Pages 1-7

  Dohmen, Takahiro ^a   Kataoka, Ei ^a   Yamada, Ikuhiro ^a   Miura, Kouichi ^a   Ohshima, Shigetoshi ^a   Shibuya, Tomomi ^a   Segawa, Daisuke ^a   Sato, Wataru ^a   Anezaki, Yumiko ^a   Ishii, Hajime ^a   Kamada, Kentaro ^a   Goto, Takashi ^a   Ohnishi, Hirohide ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Contrast enhanced ultrasonography; Hepatocellular carcinoma; Local recurrence; Radicality; Radiofrequency ablation

Indexed keywords

EPIRUBICIN; IODINATED POPPYSEED OIL; IOPAMIDOL; PERFLUBUTANE;

AGE; AGED; ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTROLLED CLINICAL TRIAL; ECHOGRAPHY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; RADIOFREQUENCY ABLATION; TUMOR RECURRENCE; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CONTRAST MEDIA; FEMALE; FERRIC COMPOUNDS; HUMANS; IRON; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXIDES; RADIO WAVES;

EID: 84855233802     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6042     Document Type: Article

References (28)

1. Bruix J, Sherman M, Llovet JM, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference European Association for the Study of the Liver. J Hepatol 35: 421-430, 2001.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
3. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103: 1201-1209, 2005.
4. Horiike N, Iuchi H, Ninomiya T. Influencing factors for recurrence of hepatocellular carcinoma treated with radiofrequency ablation. Oncol Rep 9: 1059-1062, 2002.
5. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 78(Suppl 1): 113-124, 2010.
6. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232: 381-391, 2000.
7. Hori T, Nagata K, Hasuike S, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol 38: 977-981, 2003.
8. Komorizono Y, Oketani M, Sako K, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 97: 1253-1262, 2003.
9. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228: 235-240, 2003.
10. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130, 2005.
11. Harrison LE, Koneru B, Baramipour P, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 197: 759-764, 2003.
12. Solbiati L, Ierace T, Goldberg SN, et al. Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 202: 195-203, 1997.
13. Hatanaka K, Kudo M, Minami Y, et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid®. Intervirology 51(Suppl 1): 61-69, 2008.
14. Numata K, Morimoto M, Ogura T, et al. Ablation therapy guided by contrast-enhanced sonography with Sonazoid® for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med 27: 395-406, 2008.
15. Maruyama H, Takahashi M, Ishibashi H, et al. Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int 29: 708-714, 2009.
16. Nishijima N, Ohsaki Y, Kita R, et al. Proposal of radicality grading as a criterion for therapeutic effectiveness of RFA against hepatocellular carcinoma, in relation to the local recurrence rate. Kanzo 49: 192-199, 2008 (in Japanese, Abstract in English).
17. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 5th ed. Kanehara & Co., Ltd., Tokyo Japan, 2008.
18. Mita K, Kim SR, Kudo M, et al. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 16: 4187-4192, 2010.
19. Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y, Terae S, Shirato H. Sonazoid®-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. Jpn J Radiol 27: 185-193, 2009.
20. Shiozawa K, Watanabe M, Takayama R, et al. Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid®: comparison with dynamic computed tomography. J Clin Ultrasound 38: 182-189, 2010.
21. Cioni D, Lencioni R, Rossi S, et al. Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power dopplersonography to assess treatment outcome. Am J Roentgenol 177: 783-788, 2001.
22. Solbiati L, Ierace T, Tonolini M, Cova L. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 51 (Suppl): S19-S23, 2004.
23. Hatanaka K, Kudo M, Minami Y, et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid®. Intervirology 51(suppl 1): 61-69, 2008.
24. Tanaka M, Nakashima O, Wada Y, Koga M, Kojiro M. Pathomorphological study of Kupffer cells in hepatocellular hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology 24: 807-812, 1996.
25. Xia Y, Kudo M, Minami Y, et al. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of Sonazoid®-enhanced harmonic sonography. Oncology 75 (Suppl 1): 99-105, 2008.
26. Kudo M, Hatanaka K, Chung H, Minami Y, Maekawa K. A proposal of novel treatment-assist technique for hepatocellular carcinoma in the Sonazoid®-enhanced ultrasonography: Value of defect re-perfusion imaging. Kanzo 48: 299, 2007 (in Japanese, Abstract in English).
27. Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using Sonazoid® in the management of hepatocellular carcinoma. Oncology 78(Suppl 1): 40-45, 2010.
28. Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y. Contrastenhanced sonography-guided radiofrequency ablation for the local recurrence of previously treated hepatocellular carcinoma undetected by B-mode sonography. J Clin Ultrasound 38: 339-345, 2010.